Literature DB >> 17468839

Molecular cloning and analysis of the human PCAN1 (GDEP) promoter.

Wenwen Liu1, Weiwen Chen, Pengju Zhang, Chunxiao Yu, Feng Kong, Jingti Deng, Jianye Zhang, Anli Jiang.   

Abstract

Human PCAN1 (prostate cancer gene 1) is a prostate-specific gene that is highly expressed in prostate epithelial tissue, and frequently mutated in prostate tumors. To better understand the regulation of the PCAN1 gene, a 2.6-kb fragment of its 5' flanking region was obtained by PCR. Its promoter activity was examined via the dual-luciferase reporter assay after it had been cloned into a pGL(3)-basic vector generating pGL(3)-p2.6 kb and transfected into LNCaP cells. pGL(3)-basic and pGL(3)-control were respectively used as the negative and positive controls. Sequence analysis with the MatInspector database showed that some possible binding sites for the transcriptional factors, NKX3.1, P53, SP1, cEBP and the PPAR/RXR heterodimers may locate on a 2.6-kb region upstream of the PCAN1 gene. To examine the relevant regulation of PCAN1, pGL(3)-p2.6 kb was transfected into the prostate cancer cell line LNCaP, which was treated with R1881 (10(-7) approximately 10(-9) mol/l), 17beta-estradiol (17beta-E(2), 10(-7) approximately 10(-9) mol/l), all-trans-retinoic acid (all-trans-RA, 10(-5) approximately 10(-7) mol/l) or 9-cis-retinoic acid (9-cis-RA, 10(-5) approximately 10(-7) mol/l), and eukaryotic expression plasmids of NKX3.1, p53, Sp1, Pten, PPARgamma or cEBPalpha were cotransfected with pGL(3)-p2.6 kb into LNCaP cells. pRL-TK, a Renilla luciferase reporter vector, was cotransfected into all the transfection lines as an internal control. The activities of pGL(3)-p2.6 kb (PCAN1 promoter) were analyzed via the dual-luciferase reporter assay 48 h after transfection. The results showed that 9-cis-RA enhanced the PCAN1 promoter activity in a dose-dependent manner, while R1881, 17beta-E(2) and all-trans-RA had no significant effect on PCAN1 promoter activities. Cotransfection with pGL(3)-p2.6kb and the expression plasmids of NKX3.1, p53, Sp1 or Pten respectively resulted in 1.66-, 2.48-, 2.00-and 1.72-fold 2.6 kb PCAN1 promoter activity increases relative to the controls, which were cotransfected with pcDNA3.1(+), while cotransfection of PPARgamma and cEBPalpha yielded no significant effect on PCAN1 promoter activities. These results could be applied for further study of the function and transcription regulation of the PCAN1 gene in prostate development and carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17468839      PMCID: PMC6275906          DOI: 10.2478/s11658-007-0016-z

Source DB:  PubMed          Journal:  Cell Mol Biol Lett        ISSN: 1425-8153            Impact factor:   5.787


  18 in total

1.  Differentially expressed genes in the prostate cancer cell line LNCaP after exposure to androgen and anti-androgen.

Authors:  Cláudia M Coutinho-Camillo; Sibeli Salaorni; Alvaro S Sarkis; Maria A Nagai
Journal:  Cancer Genet Cytogenet       Date:  2006-04-15

2.  Identification of a gene frequently mutated in prostate tumors.

Authors:  D J Reding; K Q Zhang; S A Salzman; J V Thomalla; R E Riepe; B K Suarez; W J Catalona; J K Burmester
Journal:  Med Oncol       Date:  2001       Impact factor: 3.064

Review 3.  Hormone refractory prostate cancer (HRPC): present and future approaches of therapy.

Authors:  G Di Lorenzo; S De Placido
Journal:  Int J Immunopathol Pharmacol       Date:  2006 Jan-Mar       Impact factor: 3.219

4.  GDEP, a new gene differentially expressed in normal prostate and prostate cancer.

Authors:  P Olsson; T K Bera; M Essand; V Kumar; P Duray; J Vincent; B Lee; I Pastan
Journal:  Prostate       Date:  2001-09-15       Impact factor: 4.104

5.  All-trans, 13-cis and 9-cis retinoic acids induce a fully reversible growth inhibition in HNSCC cell lines: implications for in vivo retinoic acid use.

Authors:  F Giannini; R Maestro; T Vukosavljevic; F Pomponi; M Boiocchi
Journal:  Int J Cancer       Date:  1997-01-17       Impact factor: 7.396

6.  Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression.

Authors:  C Bowen; L Bubendorf; H J Voeller; R Slack; N Willi; G Sauter; T C Gasser; P Koivisto; E E Lack; J Kononen; O P Kallioniemi; E P Gelmann
Journal:  Cancer Res       Date:  2000-11-01       Impact factor: 12.701

7.  1,25-dihydroxyvitamin D3 and 9-cis-retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1.

Authors:  S E Blutt; E A Allegretto; J W Pike; N L Weigel
Journal:  Endocrinology       Date:  1997-04       Impact factor: 4.736

8.  Inhibition of p53 function diminishes androgen receptor-mediated signaling in prostate cancer cell lines.

Authors:  Marcus V Cronauer; Wolfgang A Schulz; Tatjana Burchardt; Rolf Ackermann; Martin Burchardt
Journal:  Oncogene       Date:  2004-04-29       Impact factor: 9.867

Review 9.  The efficacy of 9-cis retinoic acid in experimental models of cancer.

Authors:  M M Gottardis; W W Lamph; D R Shalinsky; A Wellstein; R A Heyman
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

10.  Nkx3.1; Pten mutant mice develop invasive prostate adenocarcinoma and lymph node metastases.

Authors:  Cory Abate-Shen; Whitney A Banach-Petrosky; Xiaohui Sun; Kyriakos D Economides; Nishita Desai; Jeffery P Gregg; Alexander D Borowsky; Robert D Cardiff; Michael M Shen
Journal:  Cancer Res       Date:  2003-07-15       Impact factor: 12.701

View more
  1 in total

1.  Characterization of two functional NKX3.1 binding sites upstream of the PCAN1 gene that are involved in the positive regulation of PCAN1 gene transcription.

Authors:  Wenwen Liu; Pengju Zhang; Weiwen Chen; Chunxiao Yu; Fuai Cui; Feng Kong; Jianye Zhang; Anli Jiang
Journal:  BMC Mol Biol       Date:  2008-05-04       Impact factor: 2.946

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.